STOCK TITAN

Clearmind Medicine Inc. - $CMND STOCK NEWS

Welcome to our dedicated page for Clearmind Medicine news (Ticker: $CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medicine stock.

Clearmind Medicine Inc. (NASDAQ: CMND, FSE: CWY0) is a clinical-stage psychedelic pharmaceutical biotech company dedicated to the discovery and development of innovative psychedelic-derived therapeutics. The company focuses on addressing widespread and under-treated health issues, particularly alcohol use disorder (AUD).

Currently, Clearmind's flagship compound, CMND-100, is in the spotlight. This MEAI-based (5-methoxy-2-aminoindane) formula has shown promising pre-clinical results in disrupting binge drinking behaviors without inducing hallucinations. The Israeli Ministry of Health has recently approved a Phase I/IIa clinical trial for CMND-100, marking a significant milestone in its development.

Clearmind's intellectual property portfolio is robust and growing, comprising eighteen patent families and 27 granted patents. Recent developments include nine new patent applications filed with the USPTO, highlighting compositions for treating alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders. These efforts reflect the company's commitment to expanding and protecting its IP assets.

Collaborations play a crucial role in Clearmind's strategy. The company has entered exclusive licensing agreements with institutions such as the Hebrew University of Jerusalem, further enriching its portfolio with generation 3.0 psychedelic compounds aimed at treating addiction and mental health disorders. Additionally, Clearmind has initiated a groundbreaking partnership with Yissum Research Development Company for PTSD treatments.

Another key project is Clearmind's proprietary MEAI-based alcohol substitute beverage program. This ethanol-free alternative aligns with the growing global trend towards no- and low-alcohol consumption, offering a health-focused option for consumers.

Clearmind Medicine Inc. continues to execute its intellectual property and development strategies, positioning itself at the forefront of psychedelic-based medical treatments. The company’s shares are traded on Nasdaq under the symbol 'CMND' and on the Frankfurt Stock Exchange under 'CWY0'.

For more information, please visit their official website at www.clearmindmedicine.com or contact Investor Relations at invest@clearmindmedicine.com.

Rhea-AI Summary

Clearmind Medicine (Nasdaq: CMND) announced advancements in its MEAI-based alcohol substitute beverage program, targeting the $13 billion non-alcoholic beverages market. The company completed the last pre-clinical study needed for a novel-food application. This project, led by Nicholas Kadysh, an expert with former roles at Red Bull Canada and Juul Labs Canada, has received patents in the U.S., India, and Europe. According to IWSR, the no/low alcohol market, valued at $13 billion in 2023, is expected to grow at a CAGR of 6% through 2027. Clearmind aims to develop psychedelic-derived therapeutics for under-treated health problems, boasting a portfolio of 18 patent families and 27 granted patents.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Clearmind Medicine Inc. announces progress in its proprietary MEAI-based alcohol substitute beverage program, aiming to introduce a health-focused alternative to traditional alcoholic drinks. The company has completed pre-clinical studies for a novel-food application submission and obtained patents in the U.S., India, and Europe. Led by industry experts, the project aligns with the global trend towards no- and low-alcohol consumption in a market estimated to be over $13 billion by 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
none
-
Rhea-AI Summary

Clearmind Medicine Inc. (Nasdaq: CMND) secures global rights to innovative psychedelic compounds for PTSD treatment through an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. The global market for PTSD treatment is projected to reach $27.37 billion by 2033. Clearmind aims to revolutionize mental health care with these novel compounds, offering hope to millions worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.5%
Tags
none
Rhea-AI Summary

Clearmind Medicine Inc. has applied to cease being a reporting issuer in Canada by seeking an order from the Canadian Securities Regulators. If approved, the company will no longer be required to file financial statements and other continuous disclosure documents in Canadian jurisdictions. However, Clearmind will continue to comply with U.S. and German laws and regulations, as well as Nasdaq and FSE rules. Shareholders can access all disclosure documents on the company's website, and Canadian shareholders will receive necessary documents in line with U.S. and German requirements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
-
Rhea-AI Summary
Clearmind Medicine Inc. announces an exclusive licensing agreement with Yissum Research Development Company for generation 3.0 psychedelic compounds to treat addiction and mental disorders. The partnership aims to enhance Clearmind's IP portfolio, strengthen its leadership position, and innovate in the field of psychedelic medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
none
-
Rhea-AI Summary
Clearmind Medicine Inc. (CMND) files a patent application for 3-MMC to treat eating disorders, potentially revolutionizing the weight loss industry. The company aims to address major health issues with novel psychedelic-derived therapeutics, targeting a lucrative market with significant growth potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
none
Rhea-AI Summary
Clearmind Medicine Inc. (Nasdaq:CMND) announces significant progress in developing CMND-100, a groundbreaking MEAI-based formula, for treating alcohol use disorder (AUD) without inducing hallucinations. The Israeli Ministry of Health approved the Phase I/IIa clinical trial for CMND-100, showcasing promising pre-clinical results. Clearmind achieved various milestones in 2023, including FDA meetings, forming a Data and Safety Monitoring Board, securing IRB Approval, and partnering with renowned institutions for clinical trials. The company also unveiled positive outcomes in obesity research, collaborated with pharmaceutical leaders, and expanded its patent portfolio. Looking forward to 2024, Clearmind aims to initiate the Phase I/IIa trial for AUD, enhance strategic alliances, advance obesity research, and introduce an MEAI-based alcohol substitute, promising significant shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.86%
Tags
none
-
Rhea-AI Summary
Clearmind Medicine Inc. submits its tenth patent application under the PCT in collaboration with SciSparc for a novel composition to prevent and treat depression. The global depression and anxiety disorders treatment market size is projected to reach USD 41.83 billion by 2034.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
none
-
Rhea-AI Summary
Clearmind Medicine Inc. receives divisional patent approval from China National Intellectual Property Administration for regulating binge behaviors with primary amine aminoindan compounds, enhancing its IP protection in the psychedelic space. The company's innovative molecule, MEAI, shows promise in treating Alcohol Use Disorder and binge drinking.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none
Rhea-AI Summary
Clearmind Medicine Inc. receives approval to commence phase I/IIa clinical trial for alcohol use disorder patients using proprietary CMND-100 oral capsule. The trial aims to evaluate safety, pharmacokinetics, and efficacy of the novel psychedelic-derived therapeutic in reducing alcohol consumption.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.48%
Tags

FAQ

What is Clearmind Medicine Inc.'s primary area of focus?

Clearmind Medicine Inc. focuses on the discovery and development of novel psychedelic-derived therapeutics to address widespread and under-treated health problems, particularly alcohol use disorder (AUD).

What is CMND-100?

CMND-100 is Clearmind's flagship MEAI-based compound aimed at treating alcohol use disorder. It has shown promising pre-clinical results in reducing binge drinking without causing hallucinations.

What recent clinical developments has Clearmind made?

The Israeli Ministry of Health recently approved a Phase I/IIa clinical trial for CMND-100 to treat alcohol use disorder, marking a significant milestone in its development.

What are the key features of Clearmind's intellectual property portfolio?

Clearmind's intellectual property portfolio includes eighteen patent families and 27 granted patents, with recent additions focusing on treatments for alcohol use disorder, cocaine addiction, and obesity-related disorders.

What strategic collaborations has Clearmind entered into?

Clearmind has entered exclusive licensing agreements with the Hebrew University of Jerusalem and Yissum Research Development Company, enriching its portfolio with psychedelic compounds for treating addiction and mental health disorders.

What is Clearmind's MEAI-based alcohol substitute beverage program?

Clearmind is developing a proprietary, ethanol-free MEAI-based alcohol substitute beverage. This product aligns with the growing trend towards no- and low-alcohol consumption and aims to offer a health-focused alternative.

Where are Clearmind's shares traded?

Clearmind's shares are traded on Nasdaq under the symbol 'CMND' and on the Frankfurt Stock Exchange under the symbol 'CWY0'.

How can I contact Clearmind Medicine Inc. for more information?

For more information, you can visit their official website at www.clearmindmedicine.com or contact Investor Relations at invest@clearmindmedicine.com.

What is Clearmind's approach to intellectual property?

Clearmind is committed to expanding and protecting its intellectual property by filing additional patents and remaining opportunistic regarding the acquisition of new IP assets.

How does Clearmind ensure the safety of its novel compounds?

Clearmind's novel compounds undergo rigorous pre-clinical and clinical trials to ensure safety and efficacy before potential commercialization.

Clearmind Medicine Inc.

Nasdaq:CMND

CMND Rankings

CMND Stock Data

3.33M
3.21M
5.48%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
Vancouver